Laurus Labs — DCF analysis March 2026
29 March 2026 | Sector: Pharmaceuticals / CDMO
Laurus Labs Ltd.
Founded in 2005 by Dr. Satyanarayana Chava, Laurus Labs has evolved from a focused API supplier into one of India’s most ambitious pharmaceutical and biotechnology platforms. Headquartered in Hyderabad and listed on both NSE and BSE, the company today employs over 7,000 people — including 2,600+ scientists — across 15 manufacturing facilities approved by USFDA, EMA, WHO-Geneva, UK-MHRA, and other global regulators.
Laurus operates across two broad pillars: Generics (72% of FY25 revenues), comprising API and Finished Dosage Form (FDF) manufacturing in antiretrovirals (ARVs), oncology, cardiovascular, and other therapeutic areas; and CDMO/CMO (28% of FY25 revenues), offering integrated contract development and manufacturing services to global pharma innovators from early-stage development through commercial scale.
The company holds a world-leading position in third-party ARV API supply, with ~₹2,500 Cr in annual ARV revenues (API + formulations), and has rapidly expanded in High Potency APIs (HPAPIs), oncology, peptides, fermentation biology, and — most recently — cell and gene therapy. Its ₹3,200 Cr capex deployment over FY22–25, now being followed by ₹1,000 Cr annual investments through FY27, underpins its transition up the pharmaceutical value chain.
| Segment | FY25 Revenue (₹ Cr) | FY24 Revenue (₹ Cr) | YoY Growth | Mix % |
|---|---|---|---|---|
| CDMO – Small Molecule | 1,374 | 922 | +49% | 24.7% |
| CDMO – Bio | 160 | 160 | 0% | 2.9% |
| Generics – API | 2,438 | 2,545 | -4% | 43.9% |
| Generics – FDF | 1,582 | 1,414 | +12% | 28.5% |
| Total Revenues | 5,554 | 5,041 | +10% | 100% |
Laurus Labs’ financial trajectory reflects both the rewards and volatility of a company in aggressive transformation. After a blockbuster FY23 (boosted by a one-time ₹1,424 Cr material purchase order from a global pharma major), revenues corrected sharply in FY24 as that PO base unwound and generic ARV pricing came under pressure. The recovery began in FY25, and has accelerated significantly into FY26.
| Metric (₹ Cr) | FY22 | FY23 | FY24 | FY25 | 9M FY26 |
|---|---|---|---|---|---|
| Revenue | 4,938 | 6,041 | 5,041 | 5,554 | 5,001 |
| Gross Profit | ~2,600 | ~3,200 | ~2,600 | 3,075 | 3,006 |
| Gross Margin % | ~52% | ~53% | ~52% | 55.4% | 60.1% |
| EBITDA | ~1,200 | 1,592 | 778 | 1,116 | 1,303 |
| EBITDA Margin % | ~24% | 26.4% | 15.4% | 20.1% | 26.1% |
| PAT | ~820 | ~860 | 158 | 358 | 610 |
| CDMO Revenue | ~650 | ~1,424 (PO) | 1,082 | 1,534 | ~1,600E |
| CDMO as % of Revenue | ~13% | ~24% | 21.5% | 27.6% | ~32%E |
Key observations: The FY24 trough was driven by normalisation of the big-pharma PO, ARV pricing headwinds, and underutilised capacity from a heavy capex cycle. The rebound into FY25–26 is structurally driven — CDMO mix improving, gross margins expanding past 60%, and operating leverage kicking in. PAT has surged from ₹158 Cr in FY24 to an annualised run-rate exceeding ₹800+ Cr in FY26, representing a transformational earnings recovery.
Our DCF model anchors to a 10-year free cash flow projection, applying a WACC of 12% (reflecting India pharma risk premium and Laurus’ elevated capex intensity) and a terminal growth rate of 5%, consistent with India’s long-run nominal GDP trajectory and the structural growth of the CDMO sector globally.
Laurus’ near-term FCF generation remains modest relative to PAT due to continued heavy capex (₹1,000 Cr guided for FY26 and FY27). However, as the capex cycle peaks and new CDMO facilities ramp utilisation, FCF conversion is expected to improve materially from FY27 onwards. Our model assigns higher terminal multiples vs. traditional API peers, reflecting the CDMO mix shift and growing recurring revenue quality.
| Year | Revenue Est. (₹ Cr) | EBITDA Margin | EBITDA Est. | Capex | FCF Est. |
|---|---|---|---|---|---|
| FY26E | 7,000 | 25.5% | 1,785 | 1,000 | 400–450 |
| FY27E | 7,950 | 26.5% | 2,107 | 1,000 | 700–800 |
| FY28E | 8,695 | 27.0% | 2,348 | 800 | 1,100–1,250 |
| FY29E | 9,800 | 28.0% | 2,744 | 700 | 1,600–1,800 |
| FY30E | 11,000 | 28.5% | 3,135 | 650 | 2,000+ |
Given Laurus’ structural earnings recovery and CDMO-driven re-rating, the stock currently trades close to fair value on our base-case DCF. The three zones below represent our recommended accumulation strategy for investors with a 3–5 year horizon.
| Scenario | FY28 Revenue | FY28 PAT | EV/EBITDA Multiple | Implied Price |
|---|---|---|---|---|
| Bear | ₹6,500 Cr | ₹500 Cr | 18x | ₹550–650 |
| Base | ₹8,700 Cr | ₹1,100 Cr | 28x | ₹1,050–1,200 |
| Bull | ₹10,500 Cr | ₹1,500 Cr | 35x | ₹1,400–1,600 |
CDMO as the cornerstone of re-rating: Laurus’ CDMO division has grown from ~13% of revenues in FY22 to ~28% in FY25 and an estimated ~32% in 9M FY26. Management targets 50% CDMO contribution by FY30. With over 110 active CDMO projects (small molecules, peptides, flow chemistry, HPAPIs) and increasing late-phase conversions into commercial supply, revenue visibility is extending to multi-year timelines — a structural shift from the lumpiness of earlier years.
Fermentation and next-gen biologics: Laurus Bio (the biologics arm) has lagged in revenue contribution but represents significant optionality. Construction of a commercial-scale fermentation facility in Vizag (Phase 1: 400 KL capacity) is on track for completion by end-2026. Customer interest in dedicated fermentation lines is increasing. Combined with ADC (antibody-drug conjugate) and gene therapy development labs now operationalised in Hyderabad, the biologics platform could become a meaningful contributor by FY28–29.
KRKA JV and formulations growth: The joint venture with Slovenia-based KRKA (an FDA-compliant oral dosage facility in Hyderabad) is expected to be operational by mid-2027. This strengthens Laurus’ formulation capabilities for European and APAC markets, and adds a high-value generic FDF revenue stream.
Vizag Pharma Zone: The Andhra Pradesh government’s allotment of 532 acres for a dedicated pharmaceutical complex — with ₹5,000 Cr planned investment over 8 years — positions Laurus for a step-change in manufacturing scale beyond the current growth cycle. This represents a decade-long capacity and capability buildout.
| Growth Driver | FY26E Contribution | FY28E Contribution | Commentary |
|---|---|---|---|
| CDMO Small Mol. | ₹2,100 Cr | ₹3,000 Cr | 30% CAGR visibility; 100+ active projects |
| ARV (API + FDF) | ₹2,500 Cr | ₹2,700 Cr | Stable/modest growth; pricing normalised |
| FDF Generics | ₹1,800 Cr | ₹2,200 Cr | KRKA JV upside from FY27 |
| Non-ARV API | ₹900 Cr | ₹1,000 Cr | Oncology, cardiovascular, specialty |
| Bio / Fermentation | ₹200 Cr | ₹500+ Cr | Commercial facility online late-FY26 |
📈 Bull Catalysts
📉 Bear Risks
Laurus is best benchmarked against India-listed CDMO/API peers with significant global pharma exposure. It trades at a premium to most API peers but at a discount to pure-play CDMO comps like Syngene, reflecting its hybrid and transitioning nature.
| Company | Mkt Cap (₹ Cr) | P/E (TTM) | EV/EBITDA | Revenue CAGR (2Y) | EBITDA Margin | CDMO/CMO Mix |
|---|---|---|---|---|---|---|
| Laurus Labs | 53,400 | ~65x | ~32x | ~15% | 25–27% | 28–32% |
| Divi’s Laboratories | 1,48,000 | ~52x | ~38x | 8–10% | 32–35% | ~60% |
| Syngene International | 28,500 | ~55x | ~30x | 12–14% | 27–30% | ~100% |
| Suven Pharma | 17,000 | ~45x | ~28x | 15–18% | 38–42% | ~70% |
| Cipla | 1,05,000 | ~28x | ~18x | 8–10% | 22–24% | Low |
| Dr. Reddy’s Labs | 90,000 | ~22x | ~15x | 6–9% | 20–23% | Low |
Laurus trades at a meaningful premium to large-cap generic peers (Cipla, DRL) on account of its CDMO story and earnings recovery momentum, but at a slight discount to the purer CDMO play Divi’s — which is reasonable given Laurus’ still-evolving CDMO mix and higher leverage. As the CDMO revenue contribution crosses 35–40%, a re-rating closer to Divi’s multiples becomes plausible, but that is already partially priced in at current levels.
A Compelling CDMO Compounder, But Entry Timing Matters
Laurus Labs is executing one of the most ambitious pharmaceutical transformation stories in India — shifting from a volume-driven API supplier to a quality-driven CDMO platform. The structural tailwinds (China+1, India CDMO boom, ARV stability, fermentation build-out) are real and durable. The financial proof points — 9M FY26 PAT up 388%, EBITDA margins expanding to 27%, ROCE recovering to 16% — confirm that the capex cycle is delivering results.
However, at ~₹984 (CMP), the stock is trading close to our base-case intrinsic value of ₹920–1,050. With P/E near 65x and P/B at 11x, the valuation leaves little margin for safety. We rate the stock ACCUMULATE — ideal for patient investors willing to build positions gradually on dips below ₹900, targeting a 2–3 year horizon with a base-case price target of ₹1,200 (FY28 base). The bull case of ₹1,400–1,600 requires flawless CDMO execution and successful fermentation commercialisation.
